Article Type : Short commentary
Authors : Bando H
Keywords : Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN); Peptide Innovation for Early Diabetes Treatment (PIONEER); Semaglutide Treatment Effect in People with Obesity (STEP); Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC); Rybelsus
Glucagon-Like Peptide 1 receptor agonists (GLP-1Ras) has been evaluated for its several positive effects in the treatment of type 2 diabetes mellitus (T2DM). Semaglutide has both of injectable and oral formulations, which is beneficial. Three clinical trials were conducted, which are Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN), Peptide Innovation for Early diabetes treatment (PIONEER) and Semaglutide Treatment Effect in People with Obesity (STEP). Among them, satisfactory clinical effects of reducing HbA1c and body weight have been observed. Oral semaglutide, Rybelsus has been effective oral hypoglycemic agent (OHA) and seems to be more prescribed widely.
Diabetes has been treated
and managed for long worldwide by various association, such as International
Diabetes Federation (IDF) and American Diabetes Association (ADA). ADA
presented Standards of Medical Care in Diabetes-2022 as latest guideline in
January, 2022 [1]. Among them, development for antidiabetic agents include
Glucagon-Like Peptide 1 receptor agonists (GLP-1Ras) [2]. Several benefits of
GLP-1Ras have been gradually clarified [3]. Authors et al. have continued
clinical practice and research for diabetes, obesity, oral hypoglycemic agents
(OHAs), and others [4]. In this article, recent topics of semaglutide
(Rybelsus) will be described, as well as three clinical trials of SUSTAIN,
PIONEER and STEP in this order.
The first is Semaglutide
Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) studies
[5]. Through 10 studies of SUSTAIN,
semaglutide was found to be superior at reducing HbA1c and body weight compared
with placebo and other antidiabetic agents [6,7], including insulin glargine, sitagliptin,
exenatide extended release (ER), dulaglutide, canagliflozin, and liraglutide
[8-10]. Further, the superiority of GLP-1 RAs was found for improving glycemic
control and weight in some previous clinical trials [11]. Compared with other
GLP-1 RAs, semaglutide was superior at promoting bodyweight reduction in the
SUSTAIN clinical trials. Comparing other long-acting GLP-1 RAs of exenatide ER
and dulaglutide [8], semaglutide showed superiority in overall weight loss and
ratio of achieving more than 5% [11]. The important perspective would be
semaglutide’s place as weight reduction medication. In SUSTAIN 10 trials,
semaglutide also showed the superiority over lilraglutide, which has been
already currently marketed for weight reduction as Saxenda.
The second is Peptide
InnOvatioN for Early diabEtes tReatment (PIONEER). PIONEER are a series of
clinical trials, which were focused on weight loss and glucose variability in
T2DM patients. The antidiabetic medical agent was oral semaglutide, which has been
already introduced to actually clinical practice as Rybelsus. It has three
kinds of tablets of 3mg, 7mg and 14mg. Comparison was conducted between
semaglutide group and other comparators. Currently, semaglutide can have only
oral agents, while other GLP-Ras are all necessary for subcutaneous injection
[12]. Oral semaglutide has been made as a co-formulation of semaglutide with an
absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) [13].
It requires larger amounts per tablet, because oral formation shows lower
bioavailability.
According to the results
of PIONEER trials, oral semaglutide 7-14mg/day revealed larger HbA1c decrease
in comparison with that of sitagliptin. However, 3mg of semaglutide did not
show clinically significant improvement [14]. These results were observed in
other PIONEER clinical trials, and changes in HbA1c and weight were
significantly greater than placebo group [15,16]. Oral semaglutide showed
clinical superiority compared with other OHAs, including empagliflozin [17] and
sitaglipitin [14]. The similar superiority was also observed in the compared
studies of liraglutide [15,16] and dulaglutide [18]. After a series of SUSTAIN
trials, PIONEER clinical trials showed the results of decreased body weight and
glucose variability associated with add-on therapy to metformin mono-therapy
[12,14,15].
From the comparative
general results of semaglutide, dulaglutide and liraglutide, semaglutide showed
the superior effects of weight reduction and glucose control [15,16]. In
addition, other parameters of BMI and waist circumference were also improved.
Cases provided semaglutide showed more effects of at least 5% weight reduction
compared with other groups [15]. Semaglutide revealed weight reduction that was
dose-dependent manner with maximum efficacy at 14mg [16]. Obesity cases given
oral semaglutide tended to have remarkable weight reduction compared with that
of liraglutide [15]. Most significant weight reduction was found in 28, 36, 52
weeks, while early significant difference was observed at 26 weeks [14,15].
As regards to safety,
oral semaglutide showed non-inferiority to placebo for lowering the ratio of
major adverse cardiovascular events (MACEs) [12]. Thus, clinical benefit of
GLP-1RA would be cardioprotective and renoprotective properties. This is why
semaglutide has been highly evaluated in the clinical practice, which can be
also provided per os. In the case of renal dysfunction with 30-59% of
glomerular filtration rate (GFR), safety of semaglutide was established for
PIONEER 5 [19], associated with stable and no significant changes of GFR during
the trial. Similar to the results of SUSTAIN clinical trials, oral semaglutide
revealed no elevated risk incidence of hypoglycemia [14]. Gastrointestinal
adverse effects (GIAEs) have been commonly found such as mild to moderate
nausea and vomiting [14-18]. Further, a significant elevation of serum lipase
value was noted [20].
The third is Semaglutide
Treatment Effect in People with Obesity (STEP) trials. Primary goal of STEP was
to evaluate the effect of semaglutide as the agent for weight reduction
medication. Subjects were selected, that were based on body mass index (BMI)
and were did not suffer from T2DM. The conditions were common for the clinical
studies of STEP 1,3,4,5. In contrast, STEP 2 did not exclude T2DM, and analyzed
the data of cases with T2DM [21].
Administered dose was 2.4mg subcutaneously with once a week. Among STEP
1-4, semaglutide showed significant weight reduction than 1.0mg of semaglutide.
As to STEP2, comparison was conducted between 2.4mg vs 1.0mg, in which the
result was -9.7kg vs -2.5kg, respectively [21]. STEP 4 applied the protocol
switching from semaglutide to placebo at 20 weeks, and then 6kg weight gain was
found afterward [22]. Regarding its safety profile, mild to moderate
gastrointestinal (GI) symptoms of 2.4mg were similar to those of 10mg of oral
semaglutide. Hypoglycemic episodes were rarely reported in the protocol, which
suggest encouraging results for providing semaglutide to T2DM.
When various data of STEP
1-4 were analyzed, body weight change from baseline was -15.3kg, -9.7kg,
-16.8kg, -7.1kg, respectively [21-24]. As regards to STEP 5, the detail
analysis has been pending for summarized review at present [25]. During
clinical trials during STEP 1-5, there were no direct comparison investigation
of semaglutide 2.4 mg and other FDA-approved agents for weight reduction.
Consequently, current results seem to be fruitful achievements for effective
research on pharmacotherapeutics.
In summary, semaglutide
has novel perspectives with jnjectable and oral formulations. It has beneficial
evidence from clinical trials. Further development of research and practice
will be expected.